Prabotulinumtoxin A biosimilar by AEON Biopharma for Spasmodic Torticollis (Cervical Dystonia): Likelihood of Approval

Prabotulinumtoxin A biosimilar is under clinical development by AEON Biopharma and currently in Phase II for Spasmodic Torticollis (Cervical Dystonia).

Opinion | Lessons for Medical Practices From Hurricane Milton

Baum is a urologist. I was impressed with Gov. Ron DeSantis’s (R.-Fla.) preparations before Hurricane Milton came ashore in Florida last Wednesday night. DeSantis took

October 16, 2024

Opinion | Tanning Salons Are Overdue for a Regulatory Burn

Micevic is a dermatologist and biomedical scientist. With summer around the corner and graduation season in full swing, now is the time to remind patients

June 14, 2024

HF Patient’s Zip Code Telling of Potential Adherence Issues to Meds

Patients living in more disadvantaged neighborhoods were more likely to leave their prescriptions for standard heart failure medications unfilled, retrospective data from a large health

December 16, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.